Inotropic effects of ivabradine in the mammalian heart

Pharmacology

Volumn 86, Issue 5-6, 2010, Pages 249-258

  Boldt, Andreas ^a,b   Gergs, Ulrich ^a   Pönicke, Klaus ^a   Simm, Andreas ^a   Silber, Rolf Edgar ^a   Neumann, Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Atria; Chronotropy; Human heart; Inotropy; Ivabradine

Indexed keywords

CALCIUM CHANNEL L TYPE; CARDIOVASCULAR AGENT; CILOBRADINE; IVABRADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BYPASS SURGERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART BEAT; HEART LEFT ATRIUM; HEART MUSCLE CONTRACTILITY; HEART RIGHT ATRIUM; HUMAN; HUMAN TISSUE; INOTROPISM; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FEMALE; HEART ATRIA; HUMANS; MALE; MICE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PIPERIDINES; SPECIES SPECIFICITY; VERAPAMIL;

EID: 77958004875     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320454     Document Type: Article

References (27)

1. Davies GJ, Tzivoni D, Kobrin I: Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. Am J Cardiol 1997; 80: 34C-39C. (Pubitemid 27369154)
2. Bernink PJ, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group. Hypertension 1996; 27: 426-432.
3. Cloziel JP, Véniant M, Osterrieder W: The structurally novel Ca 2+ channel blocker Ro 40-5967, which binds to the [ 3 H]desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990; 4: 731-736.
4. Glasser SP: The relevance of T-type calcium antagonists: a profile of mibefradil. J Clin Pharmacol 1998; 38: 659-669.
5. Gergs U, Pönicke K, Neumann J: Therapie der koronaren Herzkrankheit durch bradykardisierende Substanzen: am Beispiel des Ivabradins. Ärzteblatt Sachsen-Anhalt 2007; 12: 18-21.
6. Bois P, Bescond J, Renaudon B, Lenfant J: Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996; 118: 1051-1057.
7. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P: Pharmacokinetic- pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998: 64: 192-203.
8. Di Francesco D, Camm JA: Heart rate lowering by specific and selective I (f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-1765.
9. Mistrik P, Mader R, Michalakis S, Weidinger M, Pfeifer A, Biel M: The murine HCN3 gene encodes a hyperpolarization-activated cation channel with slow kinetics and unique response to cyclic nucleotides. J Biol Chem 2005; 280: 27056-27061.
10. Schulze-Bahr E, Neu A, Friederich P, Kaupp UB, Breithardt G, Pongs O, Isbrandt D: Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest 2003; 111: 1537-1545.
11. Stieber J, Wieland K, Stockl G, Ludwig A, Hofmann F: Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol 2006; 69: 1328-1337.
12. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP: Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 37-42.
13. Cerbai E, Sartiani L, De Paoli P, Pino R, Maccherini M, Bizzarri F, Di Ciolla F, Davoli G, Sani G, Mugelli A: The properties of the pacemaker current I (f) in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol 2001; 33: 441-448.
14. Leoni AL, Marionneau C, Demolombe S, Le Bouter S, Mangoni ME, Escande D, Charpentier F: Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle. Physiol Genomics 2005; 24: 4-12.
15. Manz M, Reuter M, Lauck G, Omran H, Jung W: A single intravenous dose of ivabradine, a novel I f inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
16. Böhm M, Meyer W, Mügge A, Schmitz W, Scholz H: Functional evidence for the existence of adenosine receptors in the human heart. Eur J Pharmacol 1985; 116: 323-326.
17. Böhm M, Brückner R, Hackbarth I, Haubitz B, Linhart R, Meyer W, Schmidt B, Schmitz W, Scholz H: Adenosine inhibition of catecholamine- induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations: evidence against a cyclic AMP- and cyclic GMP-dependent effect. J Pharmacol Exp Ther 1984; 230: 483-492.
18. Neumann J, Vahlensieck U, Boknik P, Linck B, Lüss H, Müller FU, Matherne GP, Schmitz W: Functional studies in atrium overexpressing A 1 -adenosine receptors. Br J Pharmacol 1999; 128: 1623-1629.
19. Neumann J, Boknik P, Matherne GP, Lankford A, Schmitz W: Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A 1 - adenosine receptors. Br J Pharmacol 2003; 138: 209-217.
20. Kirchhefer U, Jones LR, Begrow F, Boknik P, Hein L, Lohse MJ, Riemann B, Schmitz W, Stypmann J, Neumann J: Transgenic triadin 1 overexpression alters SR Ca 2+ handling and leads to a blunted contractile response to - adrenergic agonists. Cardiovasc Res 2004; 62: 122-134.
21. Van Bogaert PP, Pittoors F: Use-dependent blockade of cardiac pacemaker current (I f ) by cilobradine and zatebradine. Eur J Pharmacol 2003; 478: 161-171.
22. Granetzny A, Schwanke U, Schmitz C, Arnold G, Schäfer D, Schulte HD, Gams E, Schipke JD: Pharmacologic heart rate reduction: effect of a novel, specific bradycardic agent on the heart. Thorac Cardiovasc Surg 1998; 46: 63-69.
23. Schipke JD, Büter I, Hohlfeld T, Schmitz- Spanke S, Gams E: Selektive I f -Kanal-Hemmung: eine Alternative in der Behandlung der koronaren Herzkrankheit? Herz 2006; 31: 55-74.
24. Koch-Weser J, Blinks JR: The influence of the interval between beats on myocardial contractility. Pharmacol Rev 1963; 15: 601-652.
25. Du XJ, Feng X, Gao XM, Tan TP, Kiriazis H, Dart AM: I f channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol 2004; 142: 107-112.
26. Pérez O, Gay P, Franqueza L, Carrón R, Valenzuela C, Delpón E, Tamargo J: Effects of the two enantiomers, S-16257-2 and S-16260- 2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. Br J Pharmacol 1995; 115: 787-794.
27. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, Berdeaux A: Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284:H676-H682.